SavedAdd your journal

Journals / Türk Onkoloji Dergisi / 2007 / Cilt: 22 - Sayı: 2

The levels of serum vascular endothelial growth factor and Bcl-2 and association between them in stage IV non-small cell lung cancer

Evre IV küçük hücreli dışı akciğer kanserinde serum vasküler endotelyal büyüme faktörü ve Bcl-2 düzeyleri ve aralarındaki ilişki

Hilal Oğuz SOYDİNÇ
Esra Ertan YAZAR
Hakan ÇAMLICA
Vildan YASASEVER
Aziz YAZAR
Faruk TAŞ
Akif ÖZGÜL
Veysel YILMAZ
Pages
76–81
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum Bcl-2 and VEGF levels were analyzed by ELISA.RESULTS The VEGF (pg/ml) level in stage IV (11 6.7± 151.7) and stage III ( 11 6.2 ± 1 4 0.6) patients was higher than healthy subjects ( 34.5 ± 6.3) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVES In most of the tumors, vascular endothelial growth fact o r (VEGF) shows its ang io g enic effects by increasing the level of the Bcl-2 onc o protein.
📊
Key Findings & Data:The aim of this study was to inv e st ig ate the serum levels of VEGF and Bcl-2 and the possible association betw een them in stage III and stage IV non-small cell lung cancer (NSCLC).
💡
Conclusion & Impact:Serum Bcl-2 and VEGF levels were analyzed by ELISA.RESULTS The VEGF (pg/ml) level in stage IV (11 6.7± 151.7) and stage III ( 11 6.2 ± 1 4 0.6) patients was higher than healthy subjects ( 34.5 ± 6.3) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVES In most of the tumors, vascular endothelial growth fact o r (VEGF) shows its ang io g enic effects by increasing the level of the Bcl-2 onc o protein. The aim of this study was to inv e st ig ate the serum levels of VEGF and Bcl-2 and the possible association betw een them in stage III and stage IV non-small cell lung cancer (NSCLC). METHODS Twenty eight patients in stage III, 24 patients in stage IV and 25 healthy subjects were enrolled in the study. Serum Bcl-2 and VEGF levels were analyzed by ELISA.RESULTS The VEGF (pg/ml) level in stage IV (11 6.7± 151.7) and stage III ( 11 6.2 ± 1 4 0.6) patients was higher than healthy subjects ( 34.5 ± 6.3) (p

Özet

AMAÇ Tümörlerin çoğunda vasküler endotelyal büyüme faktör (VEBF) angiogenik etkisini Bcl-2 onkoproteinini artırarak göstermektedir. Bu çalışmadaki amacımız evre III ve evre IV hücreli dışı akc iğer kans eri'nde (KHDAK) VEBF ve Bcl-2 düzeylerini ve aralarındaki olası ilişkiyi araştırmaktır. GEREÇ VE YÖNTEM Çalışmaya 28 evre III ve 24 evre IV KHDAK'li hasta ile kontrol grubuna sağlıklı 25 kişi alındı. ELISA yöntemi ile serum VEBF ve Bcl-2 düzeyleri çalışıldı.BULGULAR VEBF (pg/ml) düzeyi evre IV (116.7±151.7) ile evre III (116.2±140.6) hastalarda kontrollere (34.5±6.3) göre oldukça yüksek bulundu (p

🔖

Cite This Article

SOYDİNÇ, H. O., YAZAR, E. E., ÇAMLICA, H., YASASEVER, V., YAZAR, A., TAŞ, F., ÖZGÜL, A., YILMAZ, V. (2022). The levels of serum vascular endothelial growth factor and Bcl-2 and association between them in stage IV non-small cell lung cancer. Türk Onkoloji Dergisi, Cilt: 22 - Sayı: 2, 76–81. https://ajindex.com/articles/639393

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ohta M, Tsuchiya R, Shimoyama M, Sawamura K, Mori T, Miyazawa N, et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group. J Thorac Cardiovasc Surg 1993;106(4):703-8
  2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267(5203):1456-62
  3. Kondo S, Yin D, Aoki T, Takahashi JA, Morimura T, Takeuchi J. bcl-2 gene prevents apoptosis of basic fibroblast growth factor-deprived murine aortic endothelial cells. Exp Cell Res 1994;213(2):428-32
  4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-6
  5. Yano S, Nishioka Y, Goto H, Sone S. Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci 2003;94(6):479-85
  6. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;340(8812):145-6
  7. Dias S, Shmelkov SV, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002;99(7):2532-40
  8. Beierle EA, Strande LF, Chen MK. VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells. J Pediatr Surg 2002;37(3):467-71
  9. Nör JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, et al. Up Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001;61(5):2183-8
  10. Huang CI, Neuberg D, Johnson BE, Wei JY, Christiani DC. Expression of bcl 2 protein is associated with shorter survival in nonsmall cell lung carcinoma. Cancer 2003;98(1):135-43
  11. Higashiyama M, Doi O, Kodama K, Yokouchi H, Nakamori S, Tateishi R. bcl-2 oncoprotein in surgically resected non-small cell lung cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis. J Surg Oncol 1997;64(1):48-54
  12. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Cox J, Krammer B, Gatter KC, et al. bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clin Exp Metastasis 1999;17:545-54
  13. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, et al. Vascular endothelial growth factor, wild-type p53,